CELLULAR KINETICS OF ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, LISOCABTAGENE MARALEUCEL (LISO-CEL) AND ITS ASSOCIATION WITH EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

被引：0
|
作者：
Nishii, R. [1 ]
Lin, H. [1 ]
Chen, W. [1 ]
Balasubramanian, N. [1 ]
Cummings, J. [1 ]
Farazi, T. [1 ]
Fasan, O. [1 ]
Vedal, M. [1 ]
Lymp, J. [1 ]
Ogasawara, K. [1 ]
机构：
[1] Bristol Myers Squibb, Summit, NJ USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2024年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-016
引用
收藏
页码：S52 / S52
页数：1
相关论文
共 50 条
  • [21] KITE-363: A phase 1 study of an autologous anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory (R/R) B-cell lymphoma (BCL).
    Nastoupil, Loretta J.
    Dahiya, Saurabh
    Miklos, David Bernard
    Reagan, Patrick Michael
    Ulrickson, Matthew
    Jung, A. Scott
    Kloos, Ioana
    Dong, Jinghui
    Chou, Justin
    Murakami, Jodi
    Rodriguez, Katherine
    Nahas, Myrna
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [22] Good Tolerance and Durable Remission for Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Refractory/Relapsed Mantle Cell Lymphoma
    Ye, Shiguang
    Zhou, Lili
    Li, Shaoguang
    Li, Ping
    Liang, Aibin
    BLOOD, 2019, 134
  • [23] Anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study
    Tun, Aung M.
    Patel, Romil D.
    St-Pierre, Frederique
    Ouchveridze, Evguenia
    Niu, Alex
    Thordardottir, Thorunn
    Obasi, Jennifer
    Rosenthal, Allison
    Pophali, Priyanka A.
    Fenske, Timothy S.
    Karmali, Reem
    Ahmed, Sairah
    Johnston, Patrick B.
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (09) : 1712 - 1720
  • [24] Interviews of Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Lisocabtagene Maraleucel (liso-cel) Trials on Their Treatment Experience for 3 Months after Infusion
    Siddiqi, Tanya
    Jaeger, Ulrich
    Moshkovich, Olga
    Braverman, Julia
    Liu, Fei Fei
    Lanar, Sally
    Miera, Matthew
    Shah, Selam
    Devlen, Jennifer
    Salles, Gilles
    BLOOD, 2021, 138
  • [25] KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed/refractory (R/R) Mantle Cell Lymphoma (MCL): Results from Phase 2 of ZUMA-2
    Wang, Michael
    Munoz, Javier
    Goy, Andre
    Locke, Frederick
    Jacobson, Caron
    Hill, Brian
    Timmerman, John
    Holmes, Houston
    Jaglowski, Samantha
    Flinn, Ian
    McSweeney, Peter
    Miklos, David
    Pagel, John
    Kersten, Marie Jose
    Peng, Weimin
    Zheng, Lianqing
    Rossi, John
    Jain, Rajul
    Rao, Arati
    Reagan, Patrick
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 41 - 43
  • [26] Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
    Gu, Runxia
    Liu, Fang
    Zou, Dehui
    Xu, Yingxi
    Lu, Yang
    Liu, Bingcheng
    Liu, Wei
    Chen, Xiaojuan
    Liu, Kaiqi
    Guo, Ye
    Gong, Xiaoyuan
    Lv, Rui
    Chen, Xia
    Zhou, Chunlin
    Zhong, Mengjun
    Wang, Huijun
    Wei, Hui
    Mi, Yingchang
    Qiu, Lugui
    Lv, Lulu
    Wang, Min
    Wang, Ying
    Zhu, Xiaofan
    Wang, Jianxiang
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [27] Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
    Runxia Gu
    Fang Liu
    Dehui Zou
    Yingxi Xu
    Yang Lu
    Bingcheng Liu
    Wei Liu
    Xiaojuan Chen
    Kaiqi Liu
    Ye Guo
    Xiaoyuan Gong
    Rui Lv
    Xia Chen
    Chunlin Zhou
    Mengjun Zhong
    Huijun Wang
    Hui Wei
    Yingchang Mi
    Lugui Qiu
    Lulu Lv
    Min Wang
    Ying Wang
    Xiaofan Zhu
    Jianxiang Wang
    Journal of Hematology & Oncology, 13
  • [28] Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Compared with Standard of Care (SOC) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study
    Abramson, Jeremy S.
    Solomon, Scott R.
    Arnason, Jon E.
    Johnston, Patrick B.
    Glass, Bertram
    Crotta, Alessandro
    Montheard, Sandrine
    Previtali, Alessandro
    Liu, Fei Fei
    Braverman, Julia
    Guo, Shien
    Shi, Ling
    Kamdar, Manali
    BLOOD, 2021, 138 : 3845 - +
  • [29] KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL): Results of the Phase 2 ZUMA-2 Study
    Wang, Michael
    Munoz, Javier
    Goy, Andre
    Locke, Frederick L.
    Jacobson, Caron A.
    Hill, Brian T.
    Timmerman, John M.
    Holmes, Houston
    Jaglowski, Samantha
    Flinn, Ian W.
    McSweeney, Peter A.
    Miklos, David B.
    Pagel, John M.
    Kersten, Marie Jose
    Peng, Weimin
    Zheng, Lianqing
    Rossi, John M.
    Jain, Rajul K.
    Rao, Arati V.
    Reagan, Patrick M.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S1 - S1
  • [30] KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study
    Wang, Michael L.
    Munoz, Javier
    Goy, Andre
    Locke, Frederick L.
    Jacobson, Caron A.
    Hill, Brian T.
    Timmerman, John M.
    Holmes, Houston
    Jaglowski, Samantha
    Flinn, Ian W.
    McSweeney, Peter A.
    Miklos, David B.
    Pagel, John M.
    Kersten, Marie Jose
    Peng, Weimin
    Zheng, Lianqing
    Rossi, John M.
    Jain, Rajul K.
    Rao, Arati V.
    Reagan, Patrick M.
    BLOOD, 2019, 134
12345